Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer.

Area of Science:

• Oncology
• Molecular Diagnostics

Background:

• Prostate cancer is a leading cause of cancer death in men.
• Metastatic castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
• There is a critical need for biomarkers and novel therapies for advanced prostate cancer.

Purpose of the Study:

• To review clinical studies on liquid biopsies in prostate cancer, focusing on advanced stages.
• To explore the role of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.
• To discuss the progress, challenges, and future directions of liquid biopsy in prostate cancer care.

Main Methods:

• Literature review of clinical studies involving liquid biopsies in prostate cancer.
• Focus on advanced disease and specific liquid biopsy components (ctDNA, CTCs, exosomes).

Main Results:

• Liquid biopsy technologies have advanced significantly, providing insights into prostate cancer pathogenesis and treatment response.
• ctDNA, CTCs, and exosomes are key components of liquid biopsies with diagnostic and prognostic potential.
• Progress has been made, but challenges remain in the clinical application of these technologies.

Conclusions:

• Liquid biopsy is a powerful tool for understanding and managing advanced prostate cancer, including CRPC.
• Further research and technological advancements are needed to fully integrate liquid biopsy into clinical practice.
• Liquid biopsy holds promise for personalized treatment strategies and improved outcomes for prostate cancer patients.